Research programme: peptide therapeutics - Allostera Pharma

Drug Profile

Research programme: peptide therapeutics - Allostera Pharma

Alternative Names: APG 101.10; APG 2305

Latest Information Update: 30 Mar 2011

Price : $50

At a glance

  • Originator Allostera Pharma
  • Class Peptides; Small molecules
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists; Interleukin 1 receptor antagonists; Interleukin 13 receptor antagonists; Interleukin 18 inhibitors; Interleukin 23 inhibitors; Interleukin 4 receptor antagonists; Tumour necrosis factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Age-related macular degeneration; Asthma; Cancer; Chronic obstructive pulmonary disease; Emphysema; Gout; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Type 2 diabetes mellitus

Most Recent Events

  • 08 Jul 2009 Early research in Age-related macular degeneration in Canada (PO)
  • 08 Jul 2009 Early research in Asthma in Canada (PO)
  • 08 Jul 2009 Early research in Chronic obstructive pulmonary disease in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top